The World Health Organization has ‘pre-qualified’ Coartem® Baby, the first-ever malaria treatment for young infants of 4.5 kilograms or less. The combination treatment, now being rolled out in Ghana, aims to fill a longstanding gap in treatments available for children under the age of 5, who constitute three quarters of the estimated 610,000 malaria deaths […] Continue reading ->
GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts […] Continue reading ->
The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading ->
Malaria affects millions worldwide, and progress against the disease is stalling. Emerging drug resistance threatens to reverse hard-won gains, putting many more lives at risk. Public–private partnerships are racing to close the treatment gap before the current drugs begin to fail. “We believe that the eradication of malaria is in sight, but it’s an ongoing […] Continue reading ->
The first pregnant woman infected with malaria has been recruited into a Phase 3 trial in Mali that is evaluating the efficacy and safety of antimalarial drugs during the first trimester of pregnancy. Pregnant women are more susceptible to malaria as they have reduced immunity, and malaria poses serious risks to both mothers and babies. […] Continue reading ->
A new declaration by health ministers from African countries that have the highest malaria burden has reaffirmed the “unwavering commitment to the accelerated reduction of malaria mortality”. The declaration, issued Wednesday by ministers convening in Yaoundé, Cameroon at an African-wide WHO conference on malaria, aims to revitalise the campaign to drive deaths from malaria further […] Continue reading ->
The Medicines for Malaria Venture (MMV) and African Centers for Disease control signed a Memorandum of Understanding (MoU) on Thursday to providing technical support to African manufacturers of antimalarial drugs that would help bring their products up to WHO-approved standards – thus ensuring wider use of locally-produced drugs on the continent and beyond. The move […] Continue reading ->
A standardized set of more than 80 compounds with known or predicted activity against SARS-CoV-2, the virus that causes COVID-19, has been compiled by the Medicines for Malaria Venture in an effort to catalyze the discovery of drugs for the disease. The announcement comes amidst rapid shifts in the research around potential COVID-19 treatments. Just […] Continue reading ->
The combined impact of Covid-19 and malaria in regions where malaria is widespread “could be catastrophic,” warned David Reddy, CEO of Medicines for Malaria Venture (MMV), the Geneva-based product development partnership, just ahead of World Malaria Day, which is celebrated on Saturday, 25 April. His commment to Health Policy Watch, came in the wake of […] Continue reading ->
[Medicines for Malaria Venture] Geneva and Liverpool (8 March 2020) – A new collaboration announced on International Women’s Day 2020 aims to help establish pregnancy registries in malaria-endemic countries in Africa to help fill the data gap on the use of antimalarials in one of the most vulnerable populations to malaria. The study, led by […] Continue reading ->